NGS-based noninvasive minimal residual disease monitoring in patients with early non-small cell lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037419

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

lung cancer:observe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Lung cancer patients receiving treatment in Shanghai chest hospital; (2) Diagnose with lung cancer by pathology; (3) Patients with clinical TNM stage I to IIIa; (4) underwent chest CT scan before treatment; (5) Blood samples have been collected and preserved before treatment.

Exclusion criteria

Exclusion criteria: (1) Previous history of other malignant tumors; (2) patient with distant metastases; (3) pneumonectomy for other reasons; (4) patients with serious heart disease, lung dysfunction; (5) those who have previously received anti-tumor therapy; (6) mutations in ctDNA were not detected; (7) The investigator believes that it is not suitable for other situations in this trial.

Design outcomes

Primary

Measure	Time frame
Disease Free Survival;	—

Secondary

Measure	Time frame
Recurrence Rate;Tumor marker;	—

Countries

China

Contacts

Public ContactLin Wang

Shanghai Chest Hospital

wanglin987654321@126.com+86 18817314343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026